← Back to patent-cliff list
CAS 214774-58-0
2,4-dichloro-5-fluoro-3-formylbenzoic acid
Codes: FINA-004
Application context (from source-drug indications)
Otitis externaFinafloxacinOtitis media with effusionFinafloxacinOtitis mediaFinafloxacinUrinary tract infectionFinafloxacinPyelonephritisFinafloxacinGram-negative bacterial infectionFinafloxacin
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Finafloxacin | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
1-fluoro-3,5-dimethylbenzene→2,4-dichloro-1-fluoro-3,5-dimethylbenzene→2,4-dichloro-3-(dichloromethyl)-1-fluoro-5-(trichloromethyl)benzene→2,4-dichloro-5-fluoro-3-formylbenzoic acid→(Z)-2,4-dichloro-5-fluoro-3-((hydroxyimino)methyl)benzoic acid→2,4-dichloro-3-cyano-5-fluorobenzoyl chloride→(Z)-ethyl 3-(dimethylamino)acrylate→ethyl 2-(2,4-dichloro-3-cyano-5-fluorobenzoyl)-3-(dimethylamino)acrylate→cyclopropanamine→ethyl 3-(cyclopropylamino)-2-(2,4-dichloro-3-cyano-5-fluorobenzoyl)acrylate→ethyl 7-chloro-8-cyano-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate→7-chloro-8-cyano-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid→(4aS,7aS)-octahydropyrrolo[3,4-b][1,4]oxazine→(E)-but-2-ene-1,4-diol→1-tosyl-2,5-dihydro-1H-pyrrole→3-tosyl-6-oxa-3-azabicyclo[3.1.0]hexane→2-aminoethan-1-ol→4-((2-hydroxyethyl)amino)-1-tosylpyrrolidin-3-ol→2-(N-(4-hydroxy-1-tosylpyrrolidin-3-yl)-4-methylphenylsulfonamido)ethyl 4-methylbenzenesulfonate→4,6-ditosyloctahydropyrrolo[3,4-b][1,4]oxazine→(4aS,7aS)-4,6-ditosyloctahydropyrrolo[3,4-b][1,4]oxazine
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.